RNAZ
TransCode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−4.41%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$34.88M
MomentumView details →
1D Return
−4.41%
YTD Return
−69.25%
RSI (14)
24.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$34.88M
RSI (14)
24.1
MomentumView details →
1D Return
−4.41%
YTD Return
−69.25%
SummaryUpdated Jun 1, 2026
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Boston, Massachusetts. The company went public in July 2021 and focuses on developing innovative RNA-based therapeutics and diagnostics specifically targeting metastatic cancer. TransCode operates in the highly specialized field of precision oncology, utilizing advanced RNA interference (RNAi) and gene editing technologies to address one of cancer's most challenging aspects - metastasis, which occurs when cancer cells spread from their original location to other parts of the body.
Similar companies
Latest newsMore news →
TransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead therapeutic candidate TTX-MC138 produced significant survival benefits in a preclinical model of breast cancer bone metastasis.5d agoTransCode Therapeutics stockholders approved proposals to authorize the issuance of common stock and increase shares under the equity incentive plan at the reconvened annual meeting.45d ago